Physician

Mark S Abate, M.D.

According to 2025 Medicare claims, Mark Abate, M.D. (NPI: 1588778674) practices hematology/oncology in the Santa Maria-Santa Barbara, CA market, with the plurality of this provider's patient population coming from Santa Barbara, CA. This provider's primary affiliated billing organization is SANSUM CLINIC (NPI: 1932121514; TIN: 956419205) and primary practice location at 93105-4230. Abate is affiliated with the Aledade A3299 CA MSSP Enhanced (ACO ID: A3299), Caravan Collaborative Pathways (ACO ID: A4604), and Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Abate's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 443 traditional Medicare patients, billed 75,244 HCPCS/CPT codes, and received $1,391,983 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 381 prescription claims across 86 beneficiaries totaling $947,072 in drug costs, led by Lenalidomide (Lenalidomide). 2023 DME data shows 11 claims. Open Payments data shows 101 records totaling $4,152. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,234,374 and ending at $1,391,983. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,064,672 and ending at $947,072. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	437	52,705	$1,234,374
2016	363	46,760	$1,137,038
2017	372	40,888	$1,209,245
2018	395	62,009	$1,799,133
2019	420	62,736	$1,671,181
2020	390	54,664	$1,263,228
2021	388	83,755	$1,747,694
2022	374	88,089	$1,760,088
2023	344	71,374	$1,418,277
2024	443	75,244	$1,391,983

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	133	910	$1,064,672
2016	119	821	$1,011,579
2017	108	688	$913,520
2018	99	570	$680,034
2019	121	623	$1,286,151
2020	120	641	$1,113,366
2021	127	724	$1,231,575
2022	98	442	$774,473
2023	96	450	$717,404
2024	86	381	$947,072

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	53	$3,245
2016	N/R	29	$11,380
2017	N/R	27	$8,038
2018	N/R	16	$4,647
2019	N/R	43	$4,068
2020	N/R	48	$3,286
2021	N/R	33	$2,220
2022	N/R	N/R	N/R
2023	N/R	11	$3,483
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	43	134	$111
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	272	613	$98
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	73	88	$71
96372	Injection of drug or substance under skin or into muscle	49	176	$11
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	111	138	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	18	504	$270,085
Tagrisso	Osimertinib Mesylate	15	450	$254,767
Xtandi	Enzalutamide	14	420	$205,111
Eliquis	Apixaban	33	1,740	$34,878
Xarelto	Rivaroxaban	19	1,350	$25,137

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	101	$4,152	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark S. Abate, M.D.?

Tedicare shows public-source Medicare data for Mark S. Abate, M.D. (NPI 1588778674), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark S. Abate, M.D. have ACO affiliation data?

Mark S. Abate, M.D. is shown with ACO affiliation data for Aledade A3299 CA MSSP Enhanced (MSSP, ACO ID A3299), Caravan Collaborative Pathways (MSSP, ACO ID A4604), and Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Mark S. Abate, M.D.?

Mark S. Abate, M.D. is linked to SANSUM CLINIC (billing NPI 1932121514) in the available physician profile data.

Does Mark S. Abate, M.D. have Open Payments data?

Mark S. Abate, M.D. has 101 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.